The global veterinary dermatology drugs market size accounted for US$ 9.25 Bn in 2022 and is projected to reach around USD 20.95 Bn by 2030, growing at a CAGR of 10.76% from 2022 to 2030.
Report Summary
The global veterinary dermatology drugs market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the veterinary dermatology drugs market across the globe.
A comprehensive estimate on the veterinary dermatology drugs market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of veterinary dermatology drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2418
Veterinary Dermatology Drugs Market Report Scope
Report Coverage | Details |
Market Size in 2022 | USD 9.25 Billion |
Market Size by 2030 | USD 20.95 Billion |
Growth Rate from 2022 to 2030 | CAGR of 10.76% |
Largest Market | North America |
Fastest Growing Market | Asia Pacific |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segments Covered |
|
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized veterinary dermatology drugs market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: US Virtual Care Market Size To Cross USD 51.2 Bn By 2030
Veterinary Dermatology Drugs Market Players
The report includes the profiles of key veterinary dermatology drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Merial, Zoetis, Inc.
- Ceva Sante Animale
- Vetmedica
- IDEXX Laboratories
- Vetoquinol S.A.
- Virbac S.A.
- Bayer Animal Health
- Boehringer Ingelheim
- Elanco
- Novartis Animal Health
- SAVAVET
- Toray Industries
- AB Science
Market Segmentation
By Animal Type
- Companion Animal
- Livestock Animal
By Route of Administration
- Oral
- Topical
- Injectable
By Indication
- Parasitic Infections
- Allergic Infections
- Others
By Distribution Channel
- Retail
- E-Commerce
- Hospital Pharmacies
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Veterinary Dermatology Drugs Market
5.1. COVID-19 Landscape: Veterinary Dermatology Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Veterinary Dermatology Drugs Market, By Animal Type
8.1. Veterinary Dermatology Drugs Market, by Animal Type, 2022-2030
8.1.1. Companion Animal
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Livestock Animal
Chapter 9. Global Veterinary Dermatology Drugs Market, By Route of Administration
9.1. Veterinary Dermatology Drugs Market, by Route of Administration, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Veterinary Dermatology Drugs Market, By Indication
10.1. Veterinary Dermatology Drugs Market, by Indication, 2022-2030
10.1.1. Parasitic Infections
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Allergic Infections
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Veterinary Dermatology Drugs Market, By Distribution Channel
11.1. Veterinary Dermatology Drugs Market, by Distribution Channel, 2022-2030
11.1.1. Retail
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. E-Commerce
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospital Pharmacies
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Veterinary Dermatology Drugs Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.3. Market Revenue and Forecast, by Indication (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Indication (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Indication (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Indication (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Indication (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Animal Type (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Indication (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Merial, Zoetis, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Ceva Sante Animale
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Vetmedica
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. IDEXX Laboratories
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Vetoquinol S.A.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Virbac S.A.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bayer Animal Health
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Boehringer Ingelheim
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Elanco
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Novartis Animal Health
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com